Novel Technologies Impact on Parkinson’s & Alzheimer’s Patient During the COVID‑19 Pandemic

Ahmad Chitsaz, Sima Ajami


Dear Editor

The very fast outbreak and spread of the COVID‑19 made everybody surprised. In this case, there were two major issues: on the one hand, the high number of patients, and on the other hand, limited medical resources.


COVID‑19; Pandemics; Alzheimer Disease; Parkinson

Full Text:



Federico A. Experiencing COVID19 pandemic and neurology:

Learning by the recent reports and by old literary or scientific

descriptions. Neurol Sci 2020;41:1323‑7.

Schirinzi T, Lazzaro GD, Salimei Ch, Cerroni R, Liguori C,

Scalise S, et al. Physical activity changes and correlate effects in

patients with Parkinson’s disease during COVID-19 lockdown.

Mov Disord Clin Pract 2020. doi: 10.1002/mdc3.13026.

Ulrike T, Ilana S, Radu I, Maria N, Noa A, Dorina R, et al.

Detection of Alzheimer’s and Parkinson’s disease from exhaled

breath using nanomaterial‑based sensors. Nanomedicine (Lond) 2013;8:43‑56.

Mann DM, Chen J, Chunara R, Testa PA. COVID‑19 transforms

health care through telemedicine: Evidence from the field. J Am

Med Inform Assoc 2020;27:1132‑5.

de Lima ALS, Smits T, Darweesh SKL, Valenti G, Milosevic M,

Pijl M, et al. Home‑based monitoring of falls using wearable

sensors in Parkinson’s disease. Mov Disord 2020;35:109‑15.

Patel MS, Polsky D, Kennedy EH, Small DS, Evans CN,

Rareshide CAL, et al. Smartphones vs wearable devices for

remotely monitoring physical activity after hospital discharge:

A secondary analysis of a randomized clinical trial. JAMA Netw

Open 2020;53:e1920677.

Kourtis LC, Regele OB, Wright JM, Jones GB. Digital

biomarkers for Alzheimer’s disease: The mobile/wearable

devices opportunity. NPJ Digit Med 2019;2:9. doi: 10.1038/